Last updated on February 2018

SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease


Brief description of study

To investigate the efficacy of the administration of JVS-100 delivered via direct intramuscular injections on a 3 month and 6 month composite endpoint of wound progression, healing and limb loss in patients with severe peripheral arterial disease with non-healing chronic wounds who undergo an open bypass grafting or endovascular procedure for treatment of infrapopliteal disease and are dosed within 12 days and 3 months following the procedure.

Clinical Study Identifier: NCT02544204

Contact Investigators or Research Sites near you

Start Over

Craig Walker, MD

Cardiovascular Institute of the South
Houma, LA United States
  Connect »